Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

被引:419
|
作者
Kasahara, A
Hayashi, N
Mochizuki, K
Takayanagi, M
Yoshioka, K
Kakumu, S
Iijima, A
Urushihara, A
Kiyosawa, K
Okuda, M
Hino, K
Okita, K
机构
[1] Osaka Univ, Sch Med, Dept Med 1, Suita, Osaka 5650871, Japan
[2] Nagoya Univ, Sch Med, Dept Med 3, Nagoya, Aichi 466, Japan
[3] Shinshu Univ, Sch Med, Dept Med 2, Matsumoto, Nagano 390, Japan
[4] Yamaguchi Univ, Sch Med, Dept Med 1, Ube, Yamaguchi 755, Japan
关键词
D O I
10.1002/hep.510270529
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To elucidate the risk factors for liver carcinogenesis and to examine the incidence of hepatocellular carcinoma (HCC) after interferon therapy, 1,022 chronic hepatitis C patients treated with interferon were followed by ultrasonography for 13 to 97 months (median 36 months). Sustained response with prolonged alanine aminotransferase normalization was found in 313 patients, transient response with alanine aminotransferase relapse after therapy in 304, and no response in 405, Forty-six developed HCC, of whom 5 were sustained responders, 9 were transient responders, and 32 were nonresponders. The cumulative incidence of HCC in transient responders was almost equal to that in sustained responders, and it was significantly higher in nonresponders than in sustained and transient responders (P = .0009), The seventh-year cumulative incidence rates of HCC in sustained responders, transient responders, and nonresponders mere estimated to be 4.3%, 4.7%, and 26.1%, respectively. However, there was no significant difference in the cumulative incidence of HCC between patients with HCV subtype 1 and 2 (P = .14). Cox regression analysis showed that the risk of HCC development was not elevated in transient responders compared with sustained responders, but that the risk was 7.90-fold higher in nonresponders than in sustained responders (P = .008), Patients greater than or equal to 55 years of age had a significantly higher risk ratio (4.65) than did those under 55 years of age (P = .006). The risk of HCC development in men was 4.35 times higher than the risk in women (P = .02). However, the degree of fibrosis was not a significant risk factor for the development of HCC (risk ratio, 3.16; P = .052). These results suggest that patients in the high-risk group of HCC after interferon therapy were those who showed no response, those who were older, and those who were male, and that such patients should be carefully followed using ultrasonography.
引用
收藏
页码:1394 / 1402
页数:9
相关论文
共 50 条
  • [1] The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment
    Miyajima, I
    Sata, M
    Kumashiro, R
    Uchimura, Y
    Ide, T
    Suzuki, H
    Tanikawa, K
    ONCOLOGY REPORTS, 1998, 5 (01) : 201 - 204
  • [2] Incidence of hepatocellular carcinoma after interferon therapy in patients with chronic hepatitis C
    Onodera, H
    Ukai, K
    Suzuki, M
    Minami, Y
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 181 (02): : 275 - 283
  • [3] Incidence and Risk Factors for Hepatocellular Carcinoma in Patients with Chronic Hepatitis C after the Eradication of HCV
    Toyoda, Hidenori
    Kumada, Takashi
    Tada, Toshifumi
    Ito, Takanori
    HEPATOLOGY, 2013, 58 : 1168A - 1168A
  • [4] Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy
    Hayashi, K
    Kumada, T
    Nakano, S
    Takeda, I
    Kiriyama, S
    Sone, Y
    Toyoda, H
    Shimizu, H
    Honda, T
    HEPATO-GASTROENTEROLOGY, 2002, 49 (44) : 508 - 512
  • [5] Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis type C after interferon therapy
    Ishibashi, K
    Kashiwagi, T
    Suzuki, T
    Isoo, Y
    Nagasawa, M
    Toyama, T
    Ozaki, S
    Naito, M
    Azuma, M
    GASTROENTEROLOGY, 1997, 112 (04) : A1290 - A1290
  • [6] Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon
    Masafumi Ikeda
    Shigetoshi Fujiyama
    Motohiko Tanaka
    Michio Sata
    Tatsuya Ide
    Hiroshi Yatsuhashi
    Hiroshi Watanabe
    Journal of Gastroenterology, 2005, 40 : 148 - 156
  • [7] Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon
    Ikeda, M
    Fujiyama, S
    Tanaka, M
    Sata, M
    Ide, T
    Yatsuhashi, H
    Watanabe, H
    JOURNAL OF GASTROENTEROLOGY, 2005, 40 (02) : 148 - 156
  • [8] Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C
    Soga, K
    Shibasaki, K
    Aoyagi, Y
    HEPATO-GASTROENTEROLOGY, 2005, 52 (64) : 1154 - 1158
  • [9] Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C
    Hayashi, N
    Kasahara, A
    ONCOLOGY, 2002, 62 : 87 - 93
  • [10] Risk factors for hepatocellular carcinoma among chronic hepatitis C patients treated with interferon
    Kasahara, A
    Hayashi, N
    Kakumu, S
    Kiyosawa, K
    Okita, K
    HCV AND RELATED LIVER DISEASES, 1999, : 103 - 117